Yahoo Web Search

Search results

1. • Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients...

     StreetInsider· 5 days ago

     Eli Lilly and Company (NYSE: LLY) announced detailed results from SYNERGY-NASH, a phase 2 study of 190 patients, with or without type 2 diabetes, to evaluate the investigational use of tirzepatide ...

2. • Small Business - Salisbury Post | Salisbury Post

     The Salisbury Post· 6 days ago

     Eli Lilly and Company (NYSE: LLY) announced detailed results from SYNERGY-NASH, a phase 2 study of 190 patients, with or without type 2 diabetes, to evaluate the investigational use of tirzepatide ...

3. • Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients...

     The Pilot News· 6 days ago

     Eli Lilly and Company (NYSE: LLY) announced detailed results from SYNERGY-NASH, a phase 2 study of 190 patients, with or without type 2 diabetes, to evaluate the investigational use of tirzepatide ...